Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)

Phase 1 Not yet recruiting 10 enrolled Children's Hospital Medical Center, Cincinnati

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if ruxolitinib, a Janus Kinase (JAK) 1/2 inhibitor, is safe for people who have acute skin graft versus host disease (GVHD) following allogenic hematopoietic stem cell transplantation (HSCT).

Timeline

Start: 2026-10-01
Primary completion: 2029-10
Completion: 2029-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	1.5 %	Topical

Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)

Summary

Timeline

Drugs

Indications